Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) EV-to-EBIT : 15.42 (As of May. 26, 2024)

Anhui Wanbang Pharmaceutical Technology Co EV-to-EBIT Chart

Anhui Wanbang Pharmaceutical Technology Co Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial									-	-	32.00	21.15	17.67

Competitive Comparison of Anhui Wanbang Pharmaceutical Technology Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Anhui Wanbang Pharmaceutical Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anhui Wanbang Pharmaceutical Technology Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anhui Wanbang Pharmaceutical Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anhui Wanbang Pharmaceutical Technology Co's EV-to-EBIT falls into.

Anhui Wanbang Pharmaceutical Technology Co EV-to-EBIT Calculation

Anhui Wanbang Pharmaceutical Technology Co's EV-to-EBIT for today is calculated as:

Anhui Wanbang Pharmaceutical Technology Co's current Enterprise Value is ¥1,905.7 Mil.
Anhui Wanbang Pharmaceutical Technology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥123.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anhui Wanbang Pharmaceutical Technology Co  (SZSE:301520) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Anhui Wanbang Pharmaceutical Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Anhui Wanbang Pharmaceutical Technology Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥2,183.9 Mil.
Anhui Wanbang Pharmaceutical Technology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥123.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anhui Wanbang Pharmaceutical Technology Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Anhui Wanbang Pharmaceutical Technology Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Business Description